Literature DB >> 34330967

CMR-based T1-mapping offers superior diagnostic value compared to longitudinal strain-based assessment of relative apical sparing in cardiac amyloidosis.

Dennis Korthals1, Grigorios Chatzantonis1, Michael Bietenbeck1, Claudia Meier1, Philipp Stalling1, Ali Yilmaz2.   

Abstract

Cardiac amyloidosis (CA) is an infiltrative disease. In the present study, we compared the diagnostic accuracy of cardiovascular magnetic resonance (CMR)-based T1-mapping and subsequent extracellular volume fraction (ECV) measurement and longitudinal strain analysis in the same patients with (a) biopsy-proven cardiac amyloidosis (CA) and (b) hypertrophic cardiomyopathy (HCM). N = 30 patients with CA, N = 20 patients with HCM and N = 15 healthy control patients without relevant cardiac disease underwent dedicated CMR studies. The CMR protocol included standard sequences for cine-imaging, native and post-contrast T1-mapping and late-gadolinium-enhancement. ECV measurements were based on pre- and post-contrast T1-mapping images. Feature-tracking analysis was used to calculate 3D left ventricular longitudinal strain (LV-LS) in basal, mid and apical short-axis cine-images and to assess the presence of relative apical sparing. Receiver-operating-characteristic analysis revealed an area-under-the-curve regarding the differentiation of CA from HCM of 0.984 for native T1-mapping (p < 0.001), of 0.985 for ECV (p < 0.001) and only 0.740 for the "apical-to-(basal + midventricular)"-ratio of LV-LS (p = 0.012). A multivariable logistical regression analysis showed that ECV was the only statistically significant predictor of CA when compared to the parameter LV-LS or to the parameter "apical-to-(basal + midventricular)" LV-RLS-ratio. Native T1-mapping and ECV measurement are both superior to longitudinal strain measurement (with assessment of relative apical sparing) regarding the appropriate diagnosis of CA.
© 2021. The Author(s).

Entities:  

Year:  2021        PMID: 34330967     DOI: 10.1038/s41598-021-94650-2

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  34 in total

1.  Asymmetrical hypertrophy of the heart in young adults.

Authors:  D TEARE
Journal:  Br Heart J       Date:  1958-01

Review 2.  The genetics of hypertrophic cardiomyopathy: Teare redux.

Authors:  H Watkins; H Ashrafian; W J McKenna
Journal:  Heart       Date:  2008-07-24       Impact factor: 5.994

Review 3.  Hypertrophic cardiomyopathy.

Authors:  Barry J Maron; Martin S Maron
Journal:  Lancet       Date:  2012-08-06       Impact factor: 79.321

4.  Cardiac amyloidosis.

Authors:  C Cristina Quarta; Jenna L Kruger; Rodney H Falk
Journal:  Circulation       Date:  2012-09-18       Impact factor: 29.690

Review 5.  Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy.

Authors:  Ali J Marian; Eugene Braunwald
Journal:  Circ Res       Date:  2017-09-15       Impact factor: 17.367

Review 6.  Amyloidosis.

Authors:  A S Cohen
Journal:  N Engl J Med       Date:  1967-09-07       Impact factor: 91.245

7.  Systolic and diastolic ventricular function in cardiac amyloidosis. Studies in six cases diagnosed with endomyocardial biopsy.

Authors:  R H Swanton; I A Brooksby; M J Davies; D J Coltart; B S Jenkins; M M Webb-Peploe
Journal:  Am J Cardiol       Date:  1977-05-04       Impact factor: 2.778

8.  "Stiff heart" syndrome. An uncommon cause of heart failure.

Authors:  T R Kilpatrick; H M Horack; C B Moore
Journal:  Med Clin North Am       Date:  1967-07       Impact factor: 5.456

9.  New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes.

Authors:  Giovanni Palladini; Angela Dispenzieri; Morie A Gertz; Shaji Kumar; Ashutosh Wechalekar; Philip N Hawkins; Stefan Schönland; Ute Hegenbart; Raymond Comenzo; Efstathios Kastritis; Meletios A Dimopoulos; Arnaud Jaccard; Catherine Klersy; Giampaolo Merlini
Journal:  J Clin Oncol       Date:  2012-10-22       Impact factor: 44.544

10.  Diagnostic and prognostic value of subcutaneous tissue biopsy in patients with cardiac amyloidosis.

Authors:  Seiji Takashio; Yasuhiro Izumiya; Masatoshi Jinnin; Megumi Yamamuro; Sunao Kojima; Hironobu Ihn; Hisao Ogawa
Journal:  Am J Cardiol       Date:  2012-08-03       Impact factor: 2.778

View more
  4 in total

Review 1.  Advanced Imaging in Cardiac Amyloidosis.

Authors:  Dominik Waldmeier; Jan Herzberg; Frank-Peter Stephan; Marcus Seemann; Nisha Arenja
Journal:  Biomedicines       Date:  2022-04-15

Review 2.  Multimodality Imaging in the Evaluation and Prognostication of Cardiac Amyloidosis.

Authors:  Paul J Scheel; Monica Mukherjee; Allison G Hays; Joban Vaishnav
Journal:  Front Cardiovasc Med       Date:  2022-03-24

3.  Clinical and Genetic Evaluation of People with or at Risk of Hereditary ATTR Amyloidosis: An Expert Opinion and Consensus on Best Practice in Ireland and the UK.

Authors:  Julian D Gillmore; Mary M Reilly; Caroline J Coats; Rob Cooper; Helen Cox; Mark R E Coyne; Andrew J Green; Ruth McGowan; William E Moody; Philip N Hawkins
Journal:  Adv Ther       Date:  2022-04-13       Impact factor: 4.070

4.  3.0T cardiac magnetic resonance quantification of native T1 and myocardial extracellular volume for the diagnosis of late gadolinium enhancement-negative cardiac amyloidosis.

Authors:  Yumeng Liu; Jingfen Zhu; Meng Chen; Lingjie Wang; Mo Zhu; Zhen Weng; Chunhong Hu
Journal:  Ann Transl Med       Date:  2022-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.